Kirtane Ajay J, Rahman Aref M, Martinezclark Pedro, Jeremias Allen, Seto Todd B, Manning Warren J
Department of Medicine (Cardiovascular Division), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Am J Cardiol. 2006 Mar 15;97(6):891-3. doi: 10.1016/j.amjcard.2005.09.139. Epub 2006 Feb 2.
This study sought to establish the practice patterns of a diverse group of academic physicians, in the management of periprocedural anticoagulation for patients with mechanical heart valves, to study adherence to American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Physicians (n = 140) were surveyed to assess strategies for the periprocedural anticoagulation of patients with bileaflet mechanical heart valves undergoing 2 common outpatient procedures. Six patient scenarios with graded risk profiles were presented for each valve location (mitral and aortic). In >90% of high-risk patient scenarios, for which the ACC/AHA guidelines recommend periprocedural anticoagulation, anticoagulation was recommended, with minimal differences between physician specialties. However, periprocedural anticoagulation was also recommended in >70% of non-high-risk scenarios, for which the ACC/AHA guidelines recommend no periprocedural anticoagulation. Noncardiologists recommended anticoagulation more often in non-high-risk patients (p <0.01), especially for patients with aortic valve prostheses. Thus, academic physicians appropriately recommend periprocedural anticoagulation for high-risk patients with mechanical heart valves who undergo elective procedures. However, these data specifically suggest variability in practice for non-high-risk patients that are discordant with current ACC/AHA guidelines, with differences by treating specialty especially notable in this risk subset.
本研究旨在确立不同学术背景的医生在处理机械心脏瓣膜患者围手术期抗凝方面的实践模式,以研究其对美国心脏病学会/美国心脏协会(ACC/AHA)指南的遵循情况。对140名医生进行了调查,以评估接受两种常见门诊手术的双叶机械心脏瓣膜患者围手术期抗凝的策略。针对每个瓣膜位置(二尖瓣和主动脉瓣)给出了六种风险分级的患者病例。在>90%的高风险患者病例中,ACC/AHA指南建议围手术期抗凝,医生们也建议进行抗凝,不同专业的医生之间差异极小。然而,在>70%的非高风险病例中也建议进行围手术期抗凝,而ACC/AHA指南建议不进行围手术期抗凝。非心脏病专家在非高风险患者中更常建议进行抗凝(p<0.01),尤其是主动脉瓣置换患者。因此,学术医生对于接受择期手术的机械心脏瓣膜高风险患者适当建议围手术期抗凝。然而,这些数据特别表明,非高风险患者的实践存在差异,与当前ACC/AHA指南不一致,不同治疗专业之间的差异在这个风险亚组中尤为明显。